Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide
Yuhuan Li1, Robert J Lee1,2, Kongtong Yu1
1School of Life Sciences, Jilin University , Changchun 130012, China.
ACS Applied Materials & Interfaces
|September 13, 2016
Summary
A novel siRNA delivery system, sTOLP, effectively targets tumors and hepatocytes, showing potent tumor inhibition without toxicity. This breakthrough enhances siRNA stability for potential cancer therapy applications.
Area of Science:
- Biotechnology
- Nanomedicine
- RNA Therapeutics
Background:
- Clinical siRNA development is limited by inefficient delivery systems.
- Effective siRNA delivery is crucial for therapeutic applications, especially in oncology.
Purpose of the Study:
- To develop and characterize a novel multifunctional nanoparticle system for siRNA delivery.
- To evaluate the efficacy and safety of the sTOLP system for cancer therapy in vivo.
Main Methods:
- Construction of sTOLP nanoparticles using oleoyl-octaarginine (OA-R8) modified lipids, protamine-complexed siRNA, and transferrin targeting.
- In vitro optimization and characterization of sTOLP formulation for gene silencing.
- In vivo evaluation in HepG2-bearing nude mice to assess tumor inhibition, biodistribution, stability, and toxicity.
Main Results:
- sTOLP nanoparticles demonstrated excellent in vitro gene silencing activity.
- In vivo studies showed significant tumor inhibition (61.7%) with preferential uptake by tumor cells and hepatocytes.
- sTOLP-loaded siRNA exhibited enhanced stability in circulation and no significant immunogenicity or organ toxicity.
Conclusions:
- The sTOLP system represents a promising and safe delivery platform for siRNA in cancer therapy.
- This novel nanoparticle formulation overcomes key limitations in clinical siRNA development.
- sTOLP holds potential for advancing RNA-based cancer treatments.
